Localized prostate cancer shows great clinical, genetic and environmental heterogeneity;
however, prostate cancer treatment is currently guided solely by clinical staging, serum PSA …

Prostate cancer (PCa) is a prevalent malignancy that occurs primarily in old males. Prostate
tumors in different patients manifest significant inter-patient heterogeneity with respect to …

The treatment of low-risk primary prostate cancer entails active surveillance only, while high-
risk disease requires multimodal treatment including surgery, radiation therapy, and …

Abstract c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression.
Although MYC is overexpressed in both early and metastatic disease and associated with …

Stromal–epithelial interactions are critical to the morphogenesis, differentiation, and
homeostasis of the prostate, but the molecular identity and anatomy of discrete stromal cell …

Organoid technology has provided new translational research opportunities in oncology, in
part by enabling the development of patient-representative living biobanks. Prostate cancer …

Benign prostatic hyperplasia (BPH) is a progressive expansion of peri‐urethral prostate
tissue common in aging men. Patients with enlarged prostates are treated with 5‐alpha …

Despite significant therapeutic advances in recent years, treatment of metastatic prostate
cancer (PCa) remains palliative, owing to the inevitable occurrence of drug resistance …

The rapid progress of single-cell RNA-sequencing (scRNA-seq) at large scales has led to
what seemed impossible until recently: the generation of comprehensive transcriptional …

The androgen receptor (AR)-signaling pathways are essential for prostate tumorigenesis.
Although significant effort has been devoted to directly targeting AR-expressing tumor cells …